Development of a peptide-based delivery platform for targeting malignant brain tumors

Area of Science:

• Neuro-oncology
• Molecular Biology
• Biotechnology

Background:

• Human glioblastoma is a fatal brain cancer with poor outcomes despite standard treatments.
• Current therapies struggle with glioblastoma's invasive nature and cellular heterogeneity.
• Detecting and targeting diffuse disease reservoirs remains a significant clinical challenge.

Purpose of the Study:

• To develop a platform for targeting invasive and stem-like glioblastoma cells.
• To identify agents capable of delivering imaging enhancers or therapeutic cargo.
• To overcome limitations in detecting and treating glioblastoma recurrence.

Main Methods:

• Utilized a combinatorial phage display library biopanned against glioblastoma models.
• Screened candidate peptides for specificity and in vivo targeting of glioblastoma cells.
• Tested cargo-conjugated peptides for delivering imaging agents and oncolytic viruses.

Main Results:

• Identified peptides that target highly infiltrative glioblastoma populations in vivo.
• Demonstrated successful delivery of contrast agents without blood-brain barrier disruption.
• Showcased peptides' capacity to deliver therapeutic cargo, such as oncolytic viruses, to tumor cells.

Conclusions:

• Developed a peptide-based platform for innovative glioblastoma targeting.
• Peptides show utility in diagnostic/prognostic imaging and image-guided surgery.
• This platform enhances therapeutic agent delivery to glioblastoma cells, addressing disease relapse.